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INTRODUCTION:  Mondor’s  disease  (MD)  of  the  breast  is  a rare  condition  at breast  clinics.  We  do  not  have
enough  data  to establish  its  real prevalence.  As  a known  data,  most  of  the  patients  that  were  admitted  to
breast  clinics  are not  breast  cancer.  Also  MD  is a rare  entity  and diagnosing  this  entity and  informing  the
patient  about  it is  very  important.  We  present  here  this  case  to  remind  breast  clinic practitioners  that  MD
can  be seen  without  trauma  (neither  surgical  nor  physical).  Also  clinical  and  radiological  ﬁndings  and  the
treatmentof  the MD  were  discussed.
PRESENTATION OF CASE: A 35  year  old woman  was  admitted  our clinic  with  cutaneous  breast  retraction.
She  had  no risk  for thrombosis  else  using  oral  contraceptives.  Mondor’s  Disease  was  diagnosed  andral  contraceptives supported  by  radiological  ﬁndings.  Rheumatologic  and  hematologic  causes  were  also  explored.  Patient
healed  in four weeks  only  with  non-steroidal  anti-inﬂammatory  drug.
DISCUSSION: Mondor’s  Disease  is  rarely  related  with  breast  cancer.  This  rare  entity  can  be diagnosed  with
doubt  and  patient  should  be  informed  about  it.  Anti-coagulant  treatment  does  not required  if disease  is
idiopathic.
CONCLUSION:  Mondor’s  Disease  should  be reminded  at a patient  with  retracted  breast  skin.
13 T© 20
Mondor’s disease (MD) of the breast is a rare condition at breast
linics. We  do not have enough data to establish its real prevalence.1
irst description was made by a French surgeon Henri Mondor with
 cases. The main difference between Mondor’s cases and the cases
ublished before was the description of disease. Mondor described
he disease as “sub-acute subcutaneous tronculitis of the chest wall
ith a cord strong, thin, hard, isolated from any periphlebitis”.2 Also
hrombosis of the subcutaneous superﬁcial vein of the penis was
alled as “Penil MD”  in 1955.3,4 Thereafter subcutaneous thrombo-
is of different places (brachial, femoral, etc.) was  recognized with
ondor’s name.
As  a known data, most of the patients that were admitted to
reast clinics are not breast cancer. Also MD is a rare entity and
iagnosing this entity and informing the patient about it is very
mportant. We  present here this case to remind breast clinic prac-
itioners that MD  can be seen without trauma (neither surgical nor
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physical). Also clinical and radiological ﬁndings and the treatment
of the MD were discussed.
1.  Case report
A  35-year-old female was  admitted to our breast clinic with a
cutaneous retraction on her left breast since three days. She was not
a smoker and had no comorbidities. There was no breast cancer
anamnesis and no prevalence of thrombosis or thrombophlebitis
in the patient’s family history or the patient herself. No drug usage
except an oral contraceptive for contraception. She only used oral
contraceptives for contraception till 10 days. A palpable and visible
tender cord, measuring 3–4 mm in diameter and 11 cm in length
extending from lower outer quadrant of the left breast to the axilla
was seen on physical examination (Fig. 1a). Cord was also caused
retraction on the outer lower quadrant of left breast (Fig. 1b). No
breast lump was palpated.
There  were no abnormality at her whole blood count, liver
enzymes, CRP and sedimentation. Prothrombin time and INR were
normal too.
There  was an asymmetric opacity on the ½ upper part of left
Open access under CC BY license.breast in the bilateral mammography (Fig. 2a). Bilateral breast
ultrasound showed a non-compressed vascular structure with
hypo-echoic lumen (Fig. 2b). On color and power Doppler sonogra-
phy no ﬂow was observed in the vascular structure although ﬂow
 Ltd. Open access under CC BY license.
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Fig. 1. Clinical ﬁndings of the patient. (a and b) Visible cord at the upper outer quadrant of left breast. (c) Retraction on left breast lower outer quadrant.
Fig. 2. Radiological ﬁndings of the patient. (a) Asymmetric opacity on the ½ upper part of left breast. (b) Non-compressed vascular structure with hypo-echoic lumen. (c) No
ﬂow  was  observed in the vascular structure although ﬂow was observed in the vascular structures around it.
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as observed in the arterial structures around it (Fig. 2c). Venous
ow was observed at the proximal of the vascular structure.
Subsequently we consulted the patient to rheumatology clinic
or rheumatologic diseases which can cause hypercoagulability
nd hematology clinic for the other factors of hypercoagulability.
heumatologists were not in doubt from any rheumatologic dis-
ase on clinical examination and blood markers (Antiphospholipid
gG and IgM, Antids DNA) were normal. Antithrombin III, Protein C
nd Protein S levels were also normal. Genetic analyses were done
or both methylentetrahydrofolate reductase and Factor V Leiden.
utations were shown to be negative.
Patient’s thrombosis was bound to her oral contraceptive usage
ith these ﬁndings. We  decided her illness as MD  and prescribed
nly dexketoprofen 25 mg  two times a day after stopping her oral
ontraceptive use. Four weeks later she recovered the disease with-
ut any symptom or ﬁnding.
. Discussion
More than 500 reports were found on Pubmed and Medline. But
ost of these reports were case reports and literature is lack of
ide series of MD.  Also various locations of MD  can be found in
he literature. The common sites are the chest wall,2 brachial and
emoral superﬁcial veins5,6 and penis.3
Etiology of MD  differs by the location. Risk factors for penil MD
ere described as inguinal hernia repair, orchidopexy, excessive
exual activity, venous obstruction due to bladder distension, pelvic
umors, etc.6
Most cases that were located on the chest wall were traumatic
nd usually observed after breast surgery.7 Recently published
eport analyzed four largest series of MD1 which included 126
atients.8–11 Forty-one of these 126 patients were idiopathic
32.5%), 11 were due to hormone therapy (8.7%), 8 were caused by
reast cancer (6.3%) and 4 were caused by thrombophilia (3.1%).
est of the patients were caused by either surgical or physical
rauma (49.2%).1 Only one literature including 8 cases that corre-
ated MD  with hormone therapy was found in the literature.11
Salemis’s series including 5717 patients showed no breast can-
er and MD  relation.12 This data also showed that MD  was usually
ost-traumatic and idiopathic. Relation of disease with cancer was
arely reported.
Henri Mondor described the disease with a cord-like lesion on
he lateral chest wall.2 But recently cord like lesions at MD are
eported after breast augmentation surgery. Especially transaxil-
ary breast augmentation surgery is related with cord-like lesions
hat extend to the upper outer quadrant of the breast.13–15
Treatment of MD  on chest wall is symptomatic and usually
esion limits itself in 2–8 weeks. But there is no consensus on the
reatment. Also use of anticoagulants is not indicated.6,16 Some
uthors suggest anaesthetic inﬁltrations around the lesions in cases
ith pain.17,18 Also thrombectomy or superﬁcial vein resection are
uggested by some authors.19
The only drug we described was a non-steroidal anti-
nﬂammatory drug (dexketoprofen 25 mg  two times a day) and the
atient was healed seamlessly.. Conclusion
Chest wall’s MD  is a rare entity and usually limits itself in a
ew weeks. It is hard to establish its real prevalence due to this
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self-limiting condition. Etiology is usually trauma or idiopathic.
Practitioners should exclude the thrombophylic conditions at a
patient without trauma anamnesis. Breast cancer complicated with
MD is a very rare entity and usually does not require treatment.
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